' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.6
USERS' SCORE
Good
Based on 1 Reviews
8.2
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
15
Total Fat
1.5 g
2%**
Saturated Fat
0.5 g
3%**
Cholesterol
10 mg
3%
Fish Oilprovides 360 mg of Total Omega-3 Fatty Acids†comprising of:EPA (Eicosapentaenoic Acid)DHA (Docosahexaenoic Acid)Other Fatty Acids
1,200 mg (1.2 g)
***************
Top Medical Research Studies
9
Eicosapentaenoic acid benefits cholesterol
Omega-3 eicosapentaenoic polar-lipid rich extract from microalgae decreases plasma triglycerides and cholesterol in a real-world normolipidemic supplement consumer population.
Direct focus on EPA's efficacy
We explored the effects of eicosapentaenoic acid (EPA), a specific type of omega-3 fatty acid, on cholesterol levels in a recent study involving real-world supplement consumers. Participants took AlmegaPL capsules, which contain high amounts of EPA and are free of the other omega-3 fatty acid, DHA. This setup allowed us to gain insights from those who are already incorporating EPA into their diets.
Throughout the study, we monitored key health markers such as triglycerides, total cholesterol, and various types of cholesterol at different stages of supplementation. We observed that after six months of taking this supplement, participants showed a significant reduction in remnant cholesterol and maintained healthy triglyceride levels. Notably, this decrease in cholesterol did not come at the expense of raising low-density lipoprotein (LDL) levels, which is often a concern with other treatments.
These encouraging results reveal that EPA can be a beneficial addition for individuals looking to manage their cholesterol levels effectively. Importantly, our findings highlight AlmegaPL's unique position as a natural, over-the-counter option for those seeking to improve their lipid profiles.
Throughout the study, we monitored key health markers such as triglycerides, total cholesterol, and various types of cholesterol at different stages of supplementation. We observed that after six months of taking this supplement, participants showed a significant reduction in remnant cholesterol and maintained healthy triglyceride levels. Notably, this decrease in cholesterol did not come at the expense of raising low-density lipoprotein (LDL) levels, which is often a concern with other treatments.
These encouraging results reveal that EPA can be a beneficial addition for individuals looking to manage their cholesterol levels effectively. Importantly, our findings highlight AlmegaPL's unique position as a natural, over-the-counter option for those seeking to improve their lipid profiles.
Read More
9
Eicosapentaenoic acid reduces cholesterol inflammation
EPA and DHA inhibit LDL-induced upregulation of human adipose tissue NLRP3 inflammasome/IL-1β pathway and its association with diabetes risk factors.
Relevant support for cholesterol management
We explored how eicosapentaenoic acid (EPA) affects cholesterol levels and the risk of type 2 diabetes (T2D). Our study focused on individuals with high levels of atherogenic lipoproteins, specifically apoB, which are known to predict higher diabetes risk. Over a twelve-week period, participants received daily doses of EPA and docosahexaenoic acid (DHA) to see how these omega-3 fatty acids influenced the secretion of interleukin-1 beta (IL-1β) from human white adipose tissue (WAT).
Remarkably, our results showed that EPA and DHA treatment effectively normalized the IL-1β secretion levels in participants who initially had high apoB. After the intervention, LDL cholesterol no longer triggered IL-1β secretion, and the omega-3 supplementation also improved overall β-cell function and fat metabolism. This means that not only did EPA and DHA reduce inflammation linked to high cholesterol, but they also appeared to enhance metabolic health.
Additionally, we found that the supplementation reduced the association between WAT inflammasome activity and various cardiometabolic risk factors, such as increased body fat. In laboratory tests, EPA and DHA inhibited WAT IL-1β secretion in a dose-dependent manner. These findings suggest that incorporating EPA and DHA into our diets may help prevent diabetes and its related health issues in individuals with high apoB levels.
Remarkably, our results showed that EPA and DHA treatment effectively normalized the IL-1β secretion levels in participants who initially had high apoB. After the intervention, LDL cholesterol no longer triggered IL-1β secretion, and the omega-3 supplementation also improved overall β-cell function and fat metabolism. This means that not only did EPA and DHA reduce inflammation linked to high cholesterol, but they also appeared to enhance metabolic health.
Additionally, we found that the supplementation reduced the association between WAT inflammasome activity and various cardiometabolic risk factors, such as increased body fat. In laboratory tests, EPA and DHA inhibited WAT IL-1β secretion in a dose-dependent manner. These findings suggest that incorporating EPA and DHA into our diets may help prevent diabetes and its related health issues in individuals with high apoB levels.
Read More
8
EPA's effects on cholesterol explored
The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials.
Moderate confidence in findings
We examined the effects of eicosapentaenoic acid (EPA), an omega-3 fatty acid, on high cholesterol levels. In a systematic review of randomized controlled trials, we looked at studies involving at least 2 grams of EPA or its counterpart, docosahexaenoic acid (DHA).
Both EPA and DHA were found to lower triglyceride levels, with DHA appearing slightly more effective. Interestingly, we also saw that DHA increases high-density lipoprotein (HDL) cholesterol, which is known to promote heart health, while EPA does so as well, but to a lesser extent.
On the flip side, DHA has been observed to increase low-density lipoprotein (LDL) cholesterol, but it also enhances the size of LDL particles, making them less likely to contribute to artery blockages. Moreover, we noted that DHA might be more effective than EPA in reducing heart rate and blood pressure, which are essential factors in heart health.
Although both EPA and DHA show potential in promoting heart health by reducing inflammation and oxidative stress, the variations in their effects can make things complicated. We found that the evidence comparing EPA and DHA directly is limited, and more high-quality research is necessary to better understand their individual impacts on cholesterol and other cardiovascular risk factors.
Overall, while EPA has beneficial effects on cholesterol, further studies are needed to isolate these effects clearly from those of DHA.
Both EPA and DHA were found to lower triglyceride levels, with DHA appearing slightly more effective. Interestingly, we also saw that DHA increases high-density lipoprotein (HDL) cholesterol, which is known to promote heart health, while EPA does so as well, but to a lesser extent.
On the flip side, DHA has been observed to increase low-density lipoprotein (LDL) cholesterol, but it also enhances the size of LDL particles, making them less likely to contribute to artery blockages. Moreover, we noted that DHA might be more effective than EPA in reducing heart rate and blood pressure, which are essential factors in heart health.
Although both EPA and DHA show potential in promoting heart health by reducing inflammation and oxidative stress, the variations in their effects can make things complicated. We found that the evidence comparing EPA and DHA directly is limited, and more high-quality research is necessary to better understand their individual impacts on cholesterol and other cardiovascular risk factors.
Overall, while EPA has beneficial effects on cholesterol, further studies are needed to isolate these effects clearly from those of DHA.
Read More
Most Useful Reviews
5.5
Not concentrated enough
It is of high quality, but not as concentrated as I had hoped.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.6
9
Eicosapentaenoic acid aids cholesterol
Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice.
Study shows EPA's combined effects
We explored the effects of eicosapentaenoic acid (EPA) from Antarctic krill oil (ESKO) on cholesterol levels and obesity-related conditions. Through a carefully designed study involving mice on a high-fat diet, we wanted to see if ESKO could improve cholesterol metabolism and reduce fat accumulation.
We found that diets high in fat significantly increased oxidative stress and indicators associated with obesity. However, supplementation with ESKO appeared to counteract these negative effects, helping to reduce fat buildup and improve cholesterol levels.
Specifically, ESKO improved important metabolic pathways and reduced the activity of certain proteins that typically promote high cholesterol. This suggests that eicosapentaenoic acid from krill oil could play a crucial role in tackling high cholesterol and obesity-related disorders.
We found that diets high in fat significantly increased oxidative stress and indicators associated with obesity. However, supplementation with ESKO appeared to counteract these negative effects, helping to reduce fat buildup and improve cholesterol levels.
Specifically, ESKO improved important metabolic pathways and reduced the activity of certain proteins that typically promote high cholesterol. This suggests that eicosapentaenoic acid from krill oil could play a crucial role in tackling high cholesterol and obesity-related disorders.
Read More
9
Eicosapentaenoic acid reduces cholesterol inflammation
EPA and DHA inhibit LDL-induced upregulation of human adipose tissue NLRP3 inflammasome/IL-1β pathway and its association with diabetes risk factors.
Relevant support for cholesterol management
We explored how eicosapentaenoic acid (EPA) affects cholesterol levels and the risk of type 2 diabetes (T2D). Our study focused on individuals with high levels of atherogenic lipoproteins, specifically apoB, which are known to predict higher diabetes risk. Over a twelve-week period, participants received daily doses of EPA and docosahexaenoic acid (DHA) to see how these omega-3 fatty acids influenced the secretion of interleukin-1 beta (IL-1β) from human white adipose tissue (WAT).
Remarkably, our results showed that EPA and DHA treatment effectively normalized the IL-1β secretion levels in participants who initially had high apoB. After the intervention, LDL cholesterol no longer triggered IL-1β secretion, and the omega-3 supplementation also improved overall β-cell function and fat metabolism. This means that not only did EPA and DHA reduce inflammation linked to high cholesterol, but they also appeared to enhance metabolic health.
Additionally, we found that the supplementation reduced the association between WAT inflammasome activity and various cardiometabolic risk factors, such as increased body fat. In laboratory tests, EPA and DHA inhibited WAT IL-1β secretion in a dose-dependent manner. These findings suggest that incorporating EPA and DHA into our diets may help prevent diabetes and its related health issues in individuals with high apoB levels.
Remarkably, our results showed that EPA and DHA treatment effectively normalized the IL-1β secretion levels in participants who initially had high apoB. After the intervention, LDL cholesterol no longer triggered IL-1β secretion, and the omega-3 supplementation also improved overall β-cell function and fat metabolism. This means that not only did EPA and DHA reduce inflammation linked to high cholesterol, but they also appeared to enhance metabolic health.
Additionally, we found that the supplementation reduced the association between WAT inflammasome activity and various cardiometabolic risk factors, such as increased body fat. In laboratory tests, EPA and DHA inhibited WAT IL-1β secretion in a dose-dependent manner. These findings suggest that incorporating EPA and DHA into our diets may help prevent diabetes and its related health issues in individuals with high apoB levels.
Read More
9
High-purity EPA benefits cholesterol
Pleiotropic beneficial cardiometabolic actions of a high-purity eicosapentaenoic acid product in high cardiovascular risk individuals.
Pleiotropic benefits for heart health
We examined the impact of a highly purified eicosapentaenoic acid (EPA) formulation on cholesterol levels and overall heart health in individuals considered at high risk for cardiovascular issues. The study involved 226 patients who had high triglycerides and one or more cardiovascular risk factors, such as hypertension or diabetes.
Participants received 4 grams of EPA daily for three months alongside regular nutritional counseling. By tracking key health markers, we noted significant improvements in cholesterol levels, particularly in triglycerides and low-density lipoprotein (LDL). For instance, triglyceride levels dropped from an average of 2.97 mmol/L to 1.75 mmol/L in just three months.
Additionally, we found improvements in other important metrics, including total cholesterol and glucose levels, indicating that EPA supplementation may have broad benefits for cardiometabolic health. Although apolipoprotein A levels did not change significantly, the overall trend suggests that incorporating EPA could play a role in achieving better heart health outcomes.
Participants received 4 grams of EPA daily for three months alongside regular nutritional counseling. By tracking key health markers, we noted significant improvements in cholesterol levels, particularly in triglycerides and low-density lipoprotein (LDL). For instance, triglyceride levels dropped from an average of 2.97 mmol/L to 1.75 mmol/L in just three months.
Additionally, we found improvements in other important metrics, including total cholesterol and glucose levels, indicating that EPA supplementation may have broad benefits for cardiometabolic health. Although apolipoprotein A levels did not change significantly, the overall trend suggests that incorporating EPA could play a role in achieving better heart health outcomes.
Read More
9
Eicosapentaenoic acid benefits cholesterol
Omega-3 eicosapentaenoic polar-lipid rich extract from microalgae decreases plasma triglycerides and cholesterol in a real-world normolipidemic supplement consumer population.
Direct focus on EPA's efficacy
We explored the effects of eicosapentaenoic acid (EPA), a specific type of omega-3 fatty acid, on cholesterol levels in a recent study involving real-world supplement consumers. Participants took AlmegaPL capsules, which contain high amounts of EPA and are free of the other omega-3 fatty acid, DHA. This setup allowed us to gain insights from those who are already incorporating EPA into their diets.
Throughout the study, we monitored key health markers such as triglycerides, total cholesterol, and various types of cholesterol at different stages of supplementation. We observed that after six months of taking this supplement, participants showed a significant reduction in remnant cholesterol and maintained healthy triglyceride levels. Notably, this decrease in cholesterol did not come at the expense of raising low-density lipoprotein (LDL) levels, which is often a concern with other treatments.
These encouraging results reveal that EPA can be a beneficial addition for individuals looking to manage their cholesterol levels effectively. Importantly, our findings highlight AlmegaPL's unique position as a natural, over-the-counter option for those seeking to improve their lipid profiles.
Throughout the study, we monitored key health markers such as triglycerides, total cholesterol, and various types of cholesterol at different stages of supplementation. We observed that after six months of taking this supplement, participants showed a significant reduction in remnant cholesterol and maintained healthy triglyceride levels. Notably, this decrease in cholesterol did not come at the expense of raising low-density lipoprotein (LDL) levels, which is often a concern with other treatments.
These encouraging results reveal that EPA can be a beneficial addition for individuals looking to manage their cholesterol levels effectively. Importantly, our findings highlight AlmegaPL's unique position as a natural, over-the-counter option for those seeking to improve their lipid profiles.
Read More
8
Icosapent ethyl reduces cardiovascular events
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Addresses cholesterol and cardiovascular risks
We examined the effects of icosapent ethyl, a form of eicosapentaenoic acid, on patients with high cholesterol, specifically those who also have elevated triglyceride levels. In this analysis of the REDUCE-IT trial, we focused on statin-treated individuals who had a high risk of cardiovascular problems and found that the treatment could lower the occurrence of serious cardiovascular events.
The study included a significant number of patients who were divided based on their low-density lipoprotein cholesterol (LDL-C) levels. An interesting finding was that icosapent ethyl appeared to benefit both groups—those with LDL-C levels below 55 mg/dL and those with levels at or above 55 mg/dL. For patients with very well-controlled cholesterol, the treatment resulted in a lower rate of cardiovascular issues compared to a placebo, indicating its effectiveness even among those managing their cholesterol well.
While we did find that icosapent ethyl could help manage cardiovascular risks in patients with heightened cholesterol, it's essential to clarify that the study primarily focused on the rate of cardiovascular events rather than a direct impact purely on cholesterol levels. Overall, our findings suggest that even patients with optimal cholesterol control can still gain benefits from this treatment regarding cardiovascular health.
The study included a significant number of patients who were divided based on their low-density lipoprotein cholesterol (LDL-C) levels. An interesting finding was that icosapent ethyl appeared to benefit both groups—those with LDL-C levels below 55 mg/dL and those with levels at or above 55 mg/dL. For patients with very well-controlled cholesterol, the treatment resulted in a lower rate of cardiovascular issues compared to a placebo, indicating its effectiveness even among those managing their cholesterol well.
While we did find that icosapent ethyl could help manage cardiovascular risks in patients with heightened cholesterol, it's essential to clarify that the study primarily focused on the rate of cardiovascular events rather than a direct impact purely on cholesterol levels. Overall, our findings suggest that even patients with optimal cholesterol control can still gain benefits from this treatment regarding cardiovascular health.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Reviews
8.2
5.5
Not concentrated enough
It is of high quality, but not as concentrated as I had hoped.
